Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Calpains participate in the expression, activity and secretion of MMP2 and MMP9. by Muhammad Yasir Asghar (423105)

Increased 5-hmC occurs in osteoblast and chondrocyte gene promoters. by Richard C. Lindsey (7148168)

“…(B) Inhibition of PHD2 with Iox2 significantly decreased 5-hmC levels in the promoters of chondrocyte genes HIF1α and VEGF. …”

Restoring large-scale brain networks in PTSD and related disorders: a proposal for neuroscientifically-informed treatment interventions by Ruth A. Lanius (3121746)

Principal components analysis (a) and redundancy analysis (RDA) on 12 soil parameters as influenced by land-use management systems [Agri: Agriculture; Bioen: Bioenergy; CRP: Conser... by Emmanuel Amoakwah (13228938)

Syntaxin 5 Is Required for Copper Homeostasis in <em>Drosophila</em> and Mammals by Melanie Norgate (234832)

“…<div><p>Copper is essential for aerobic life, but many aspects of its cellular uptake and distribution remain to be fully elucidated. A genome-wide screen for copper homeostasis genes in <em>Drosophila melanogaster</em> identified the SNARE gene <em>Syntaxin 5</em> (<em>Syx5</em>) as playing an important role in copper regulation; flies heterozygous for a null mutation in <em>Syx5</em> display increased tolerance to high dietary copper. …”

The effect of low pH on the absorbance spectra of Rtms5^Y67F and Rtms5^Y67F/H146S. by Jion M. Battad (127989)

“…<p>Rtms5^Y67F (A) and Rtms5^Y67F/H146S (B) at a protein concentration of 0.25 mg/ml in 0.1 M potassium phosphate, pH 2.3 were incubated at 21°C and the absorption spectra determined at selected time points. …”

<i>N</i>⁶-methyladenosine modification and the YTHDF2 reader protein play cell type specific roles in lytic viral gene expression during Kaposi's sarcoma-associated herp... by Charles R. Hesser (5147309)

“…In iSLK.219 cells the defect was linked to their roles in the post-transcriptional accumulation of the major viral lytic transactivator ORF50, which is m⁶A modified. In contrast, although the ORF50 mRNA was also m⁶A modified in KSHV infected B cells, ORF50 protein expression was instead increased upon depletion of METTL3, or, to a lesser extent, YTHDF2. …”

Glycomic Analysis Reveals a Conserved Response to Bacterial Sepsis Induced by Different Bacterial Pathogens by Daniel W. Heindel (1321224)

HlyA is responsible for UPEC persistence in the bladder. by Manisha Naskar (2613763)

The laminar structure of null eyes is normal after 5 days of development by Curtis R French (33212)

Image 5_Clinical trials in otology and neurotology: state of the science.jpeg by Lindsay S. Moore (15003347)

“…Compared to 2008–2018, trends included a shift towards device and procedural interventions for vestibular disorders and a decrease in device trials and increase in behavioral interventions for tinnitus. …”

HBoV1-3 IgG stability among 109 constitutionally healthy children. by Kalle Kantola (801531)

“…<p>Abbreviations: HBoV1, human bocavirus 1; HBoV2, human bocavirus 2; HBoV3, human bocavirus 3; IgG, immunoglobulin G</p><p>^a Competed IgG showed no significant waning and remained above 2.0 absorbance units from initial seroconversion to the end of the follow-up period</p><p>^b ≥2 absorbance unit decrease in optical density after seroconversion</p><p>^c ≥2 absorbance unit increase in optical density in two consecutive samples, both obtained at least 4 months after IgG seroconversion</p><p>Note: the percentages do not necessarily add up to 100% because of rounding up.…”

Table_1_Strategy and Performance Evaluation of Low-Frequency Variant Calling for SARS-CoV-2 Using Targeted Deep Illumina Sequencing.XLSX by Laura A. E. Van Poelvoorde (11257779)

“…<p>The ongoing COVID-19 pandemic, caused by SARS-CoV-2, constitutes a tremendous global health issue. …”

Reduced control model M5: No accumulation of information across trials. by Veith Weilnhammer (2909060)

“…<p>When simulating data for the <i>no-evidence-accumulation model</i>, we removed the accumulation of information across trials by setting the hazard rate <i>H</i> to 0.5. Simulated data thus depended only on the participant-wise estimates for the amplitudes <i>a</i>_{<i>LLR</i>/<i>ψ</i>}, frequency <i>f</i>, phase <i>p</i>, and inverse decision temperature <i>ζ</i>. …”